 He criticized Hemispherx and its rintatolimod results, alleging a variety of misdemeanors, including accusations of refusing to supply rintatolimod after clinical trials have ended, and issuing misleading results to widen markets for rintatolimod.In 1998, Hemispherx Biopharma filed a complaint against Asensio and his company, alleging defamation, conspiracy and interference with its business relations through a short-selling plot.After a jury rejected the defamation claims against Asensio, a mistrial was declared.